TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $4,377,000 | +28.0% | 141,000 | 0.0% | 1.21% | +34.6% |
Q3 2021 | $3,419,000 | +37.5% | 141,000 | -17.3% | 0.90% | +55.5% |
Q2 2021 | $2,487,000 | -52.7% | 170,484 | -19.0% | 0.58% | -60.5% |
Q1 2021 | $5,256,000 | +152.1% | 210,484 | +175.2% | 1.46% | +87.5% |
Q4 2020 | $2,085,000 | – | 76,484 | – | 0.78% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |